TL;DR
This study provides a comprehensive landscape of FGFR aberrations in a large Chinese non-small cell lung cancer (NSCLC) population, revealing actionable targets for therapy. The findings highlight the prevalence of FGFR mutations, gene amplifications, and novel fusions, suggesting potential combination therapies and new avenues for precision medicine in NSCLC.
What Problem Does This Paper Address?
The fibroblast growth factor receptor (FGFR) signaling pathway is implicated in various cancers, including non-small cell lung cancer (NSCLC). However, the specific spectrum and frequency of FGFR alterations (mutations, fusions, and amplifications) in the Chinese NSCLC population, and their clinical implications, were not well-characterized. Understanding these aberrations is crucial for identifying patients who might benefit from targeted FGFR inhibitors and for developing effective treatment strategies, especially given the increasing interest in targeting this pathway.
Methods
The researchers employed comprehensive genomic profiling using hybridization capture-based next-generation sequencing (NGS) to analyze tumor specimens and/or circulating cell-free DNA (cfDNA) from a large cohort of NSCLC patients. Specifically, they targeted over 400 cancer-relevant genes, including all exons and flanking intronic regions of FGFR1-4, to detect mutations, gene rearrangements (fusions), and gene amplifications. Standard bioinformatics pipelines were used for data processing, including read mapping, variant calling (SNPs and indels), and fusion detection using tools like BWA, GATK, VarScan2, and FACTERA. Clinical data, including patient demographics and treatment histories, were also collected and analyzed.
Datasets
The study analyzed data from a total of 15,150 individual clinical lung cancer patients. For the specific analysis of FGFR aberrations, a validated dataset of 10,966 patients was used. This dataset comprised tumor tissue samples and, in some cases, liquid biopsies (plasma and pleural effusion samples). Matched normal whole blood samples were used as germline controls.
Key Insights and Ideas
- FGFR aberrations are present in a significant subset of NSCLC patients: The study establishes that FGFR alterations are not rare, affecting nearly 2% of the NSCLC population analyzed.
- Histology matters: FGFR abnormalities are significantly more common in lung squamous cell carcinoma (LUSC) than in lung adenocarcinoma (LUAC), suggesting a potential subtype-specific role for FGFR signaling.
- Co-occurring alterations are common and clinically relevant: A substantial proportion of patients with FGFR mutations also harbor alterations in the PI3K pathway (e.g., PIK3CA, PIK3R2). This points towards potential combination therapeutic strategies targeting both FGFR and PI3K signaling.
- FGFR fusions can mediate resistance to EGFR inhibitors: The identification of FGFR fusions in patients previously treated with EGFR TKIs suggests that these fusions might represent an acquired resistance mechanism, highlighting the complexity of treatment resistance.
- Novel FGFR fusions identified: The study reports the discovery of novel FGFR fusions (e.g., SLC20A2-FGFR1, FGFR4-RAPGEFL1), expanding the known landscape of FGFR alterations and offering new targets for investigation.
- FGFR aberrations are largely mutually exclusive: While co-occurring alterations in other pathways are noted, the primary FGFR aberrations (mutations, fusions, amplifications) tend to occur independently, simplifying the interpretation of actionable targets.
Key Results
- FGFR aberrations were detected in 1.9% (210/10,966) of the NSCLC population.
- FGFR abnormalities were significantly more frequent in LUSC (6.8%) compared to LUAC (1.3%).
- FGFR oncogenic mutations were found in 19 patients (~0.17%), with 68% being male LUSC patients.
- 58% (11/19) of FGFR-mutated patients had concurrent altered PI3K signaling.
- FGFR fusions retaining the intact kinase domain were identified in 0.11% (12/10,966) of patients, including novel fusions like FGFR4-RAPGEFL1 and SLC20A2-FGFR1.
- FGFR amplification was detected in 24 patients, with the majority being FGFR1 amplifications (87.5%).
- Concomitant EGFR mutations or amplifications were observed in 6 of the 12 FGFR fusion patients.
Limitations and Future Work
The authors acknowledge that the prevalence of FGFR alterations in their Chinese NSCLC cohort was lower than reported in some previous studies, which may be attributed to ethnic differences, cohort size, or the inclusion of liquid biopsy samples. They also note that for some patients with FGFR mutations, pretreatment samples were unavailable, limiting the ability to definitively link acquired resistance to specific alterations.
Future work could focus on:
- Investigating the therapeutic efficacy of FGFR inhibitors in NSCLC patients with identified FGFR aberrations, particularly in LUSC.
- Exploring combination therapies targeting both FGFR and PI3K pathways in patients with co-occurring alterations.
- Further validating the functional significance and clinical utility of the novel FGFR fusions identified in this study.
- Conducting larger, multi-center studies to confirm these findings and explore the role of FGFR signaling in different NSCLC subtypes and treatment settings.
Summary updated